Unit 6: Research ethics

Research ethics governs how investigators treat human participants, data, and the wider society affected by their work. It rests on three foundational documents whose principles every later section restates: the Nuremberg Code (1947, born from Nazi medical trials), the Declaration of Helsinki (World Medical Association, 1964), and the Belmont Report (US, 1979).

• Respect for persons: treat individuals as autonomous agents and protect those with diminished autonomy through informed consent.
• Beneficence: maximise benefit and minimise harm — the working rule behind risk–benefit analysis.
• Justice: distribute the burdens and benefits of research fairly, so no group is exploited or excluded.
• Voluntary informed consent: the Nuremberg Code's first article — participation must be free, informed, and revocable.
• Priority of the subject: Helsinki's rule that the wellbeing of the individual overrides the interests of science and society.

II. Institutional Review Board (IRB): Gatekeeper of human-subjects research

A. Definition and composition

An IRB (called an Ethics Committee or IEC elsewhere) is a formally constituted body that reviews and monitors research involving human participants before it may proceed.

• Legal mandate: required by US regulation 45 CFR 46 ("Common Rule") for federally funded studies; equivalents exist under ICH-GCP guidelines worldwide.
• Membership: at least five members of mixed expertise, including one scientist, one non-scientist, and one member unaffiliated with the institution to guard against conflict of interest.

B. Functions

The IRB's function is to ensure a study is ethically acceptable, not merely scientifically sound.

• Protocol review: examines study design, consent forms, and recruitment methods before approval.
• Risk–benefit judgement: approves only when risks are minimised and reasonable relative to anticipated benefits.
• Consent oversight: verifies that consent documents are complete, understandable, and free of coercive language.
• Continuing review: re-approves ongoing studies at least annually and reviews adverse events and protocol amendments.
• Authority to act: may approve, require modification, or disapprove, and can suspend research that endangers subjects.

III. Ethical issues in clinical research

Clinical research tests interventions on people, so the tension between generating knowledge and protecting participants is sharpest here.

A. Ethical issues in clinical research

The central issues concern consent, honesty, and the design of comparisons.

• Informed consent: disclosure of purpose, procedures, risks, alternatives, and the right to withdraw — violated in the Tuskegee Syphilis Study (1932–1972), where treatment was withheld without consent.
• Placebo use: ethically contested when an effective standard treatment exists, since the control group is denied known benefit.
• Clinical equipoise: a trial is justified only when genuine uncertainty exists about which arm is better.
• Deception and disclosure: withholding information may bias results but undermines autonomy; requires debriefing.
• Conflict of interest: industry funding can bias design, analysis, and selective publication of favourable results.

B. Vulnerable populations

Some groups cannot fully protect their own interests and need extra safeguards.

• Who qualifies: children, prisoners, pregnant women, cognitively impaired persons, and the economically or educationally disadvantaged.
• Diminished autonomy: prisoners may consent under implicit coercion; children cannot give legal consent, only assent alongside parental permission.
• Additional protections: independent advocates, restricted risk levels, and IRB scrutiny of why the vulnerable group is even needed.
• Justice concern: the poor should not bear research burdens for benefits that reach only the wealthy — a fair-subject-selection requirement.

C. Risks and benefits

Every protocol requires a systematic weighing of harms against expected gains.

• Risk types: physical, psychological, social (stigma), economic, and loss of privacy.
• Minimisation: use the least invasive procedure and sound design so no subject is exposed to avoidable harm.
• Benefit categories: direct benefit to the participant versus generalisable knowledge for society; the two must not be conflated during consent.
• Minimal risk standard: harm no greater than that of daily life or routine examination — the threshold for expedited review and for research on children.
• Favourable ratio: approval requires that anticipated benefits justify the residual risk, per beneficence.

D. Human protectionism

This is the overarching commitment that participants are ends in themselves, never mere instruments of data collection.

• Primacy of the person: subject welfare outranks the completion of the study.
• Structural safeguards: IRB review, informed consent, data confidentiality, and the right to withdraw without penalty operationalise the principle.
• Historical driver: abuses at Nuremberg, Tuskegee, and Willowbrook (hepatitis studies on institutionalised children) prompted codified human-subject protections.
• Ongoing monitoring: Data Safety Monitoring Boards can halt a trial early if harm or clear benefit emerges.

IV. Authorship and integrity in research

A. Authorship

Authorship assigns credit and accountability for a published work and is itself an ethical matter.

• ICMJE criteria: an author must (1) contribute substantially to conception or analysis, (2) draft or revise it critically, (3) approve the final version, and (4) agree to be accountable.
• Guest authorship: listing a senior figure who did not contribute — inflates credit dishonestly.
• Ghost authorship: omitting a real contributor, often an industry writer, hiding conflicts of interest.
• Order and dispute: first author typically did the most work; corresponding author bears communication responsibility — agree early to avoid conflict.

B. Issues in research ethics

Beyond authorship, research integrity covers a family of misconduct and responsibility issues.

• FFP misconduct: Fabrication (inventing data), Falsification (manipulating data), and Plagiarism (using others' work as one's own) are the primary offences.
• Data management: honest recording, retention, and availability for verification.
• Publication ethics: avoiding duplicate publication, salami-slicing one study into many papers, and undisclosed conflicts.
• Peer review integrity: confidentiality and freedom from bias in reviewing others' work.
• Whistleblowing: protected channels to report misconduct without retaliation.

V. Ethical issues in human cloning, reproduction and stem cell research

Manipulating human embryos and cells raises questions about the moral status of the embryo and the limits of intervention.

A. Human cloning reproduction

Two purposes must be distinguished because they carry different ethical weight.

1. Reproductive cloning: creating a genetically identical human via somatic cell nuclear transfer — widely banned for safety (high failure and abnormality rates seen in Dolly-era animals), loss of genetic uniqueness, and threats to identity and dignity.
2. Therapeutic cloning: creating cloned embryos to derive tissues for treatment — objected to because it produces embryos solely to destroy them, but defended for its medical promise.

• Consent and welfare: a cloned child cannot consent to the conditions of its creation.
• Commodification: treating human reproduction as manufacture undermines respect for persons.

B. Stem cells research

Stem cells can self-renew and differentiate, making them valuable but ethically charged depending on their source.

• Embryonic stem cells (ESCs): derived from the blastocyst inner cell mass; harvesting destroys the embryo, the core objection for those who grant the embryo full moral status.
• Adult (somatic) stem cells: ethically uncontroversial but more limited in potency.
• Induced pluripotent stem cells (iPSCs): adult cells reprogrammed to embryonic-like states, largely bypassing the embryo-destruction dilemma.
• Governance concerns: egg-donor exploitation, informed consent for tissue use, and just access to resulting therapies.

VI. Social and ethical implications of biological weapons

Biological weapons use pathogens or toxins to cause mass harm, placing life-science research at the centre of security ethics.

• Legal ban: the Biological Weapons Convention (1972) prohibits development, production, and stockpiling of biological agents for hostile use.
• Dual-use dilemma: the same research that develops vaccines can be repurposed to enhance pathogen virulence or transmissibility.
• Publication tension: open science versus the risk that methods (e.g. synthesising or enhancing a virus) provide a blueprint for misuse.
• Indiscriminate harm: biological agents cannot distinguish combatants from civilians and may spread uncontrollably across borders and generations.
• Researcher responsibility: scientists share moral accountability for foreseeable malicious applications of their work — the basis for biosecurity oversight and codes of conduct.

VII. Euthanasia

Euthanasia is the deliberate ending of a life to relieve suffering, sitting at the intersection of medical ethics and autonomy.

• Active vs passive:
  • Active: a direct act, such as a lethal injection, that causes death.
  • Passive: withholding or withdrawing life-sustaining treatment, allowing death to occur.
• Voluntary, non-voluntary, involuntary: with the patient's request, without an available request (incompetent patient), and against the patient's wishes, respectively — the last is ethically indefensible.
• Physician-assisted suicide: the physician provides the means, but the patient performs the final act.
• Arguments for: respect for autonomy, relief of intractable suffering, and dignity in dying.
• Arguments against: sanctity of life, the risk of a slippery slope toward pressuring the vulnerable, and conflict with the physician's duty to heal.
• Palliative alternative: hospice and pain control are offered as a means to address suffering without hastening death.